Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study.
Satish K Garg, David Liljenquist, Bruce Bode, Mark P Christiansen, Timothy S Bailey, Ronald L Brazg, Douglas S Denham, Anna R Chang, Halis Kaan Akturk, Andrew Dehennis, Katherine S Tweden, Francine R Kaufman
Author Information
Satish K Garg: University of Colorado, Aurora, Colorado, USA.
David Liljenquist: Rocky Mountain Diabetes Center, Idaho Falls, Idaho, USA.
Bruce Bode: Atlanta Diabetes Associates, Atlanta, Georgia, USA.
Mark P Christiansen: Diablo Clinical Research, Walnut Creek, California, USA.
Timothy S Bailey: AMCR Institute, Escondido, California, USA. ORCID
Ronald L Brazg: Rainier Clinical Research Center, Renton, Washington, USA.
Douglas S Denham: Clinical Trials of Texas, Inc., San Antonio, Texas, USA.
Anna R Chang: John Muir Health, Concord, California, USA.
Halis Kaan Akturk: University of Colorado, Aurora, Colorado, USA. ORCID
Andrew Dehennis: Senseonics, Inc., Germantown, Maryland, USA.
Katherine S Tweden: Senseonics, Inc., Germantown, Maryland, USA. ORCID
Francine R Kaufman: Senseonics, Inc., Germantown, Maryland, USA.
Use of continuous glucose monitoring (CGM) systems is being rapidly adopted as standard of care for insulin-requiring patients with diabetes. The PROMISE study (NCT03808376) evaluated the accuracy and safety of the next-generation implantable Eversense CGM system for up to 180 days. This was a prospective multicenter study involving 181 subjects with diabetes at 8 USA sites. All subjects were inserted with a primary sensor. Ninety-six subjects had a second sensor, either an identical sensor or a modified sensor (sacrificial boronic acid [SBA]), inserted in their other arm (53 and 43 subjects, respectively). Accuracy was evaluated by comparing CGM to YSI 2300 glucose analyzer (Yellow Springs Instrument [YSI]) values during 10 clinic visits (day 1-180). Confirmed event detection rates, calibration stability, sensor survival, and serious adverse events (SAEs) were evaluated. For primary sensors, the percent CGM readings within 20%/20% of YSI values was 92.9%; overall mean absolute relative difference (MARD) was 9.1%. The confirmed alert detection rate at 70 mg/dL was 93% and at 180 mg/dL was 99%. The median percentage of time for one calibration per day was 56%. Sixty-five percent of the primary sensors survived to 180 days. For the SBA sensors, the percent CGM readings within 20%/20% of YSI values was 93.9%; overall MARD was 8.5%. The confirmed alert detection rate at 70 mg/dL was 94% and at 180 mg/dL was 99%. The median percentage of time for one calibration per day was 63%. Ninety percent of the SBA sensors survived to 180 days. No device- or insertion/removal procedure-related SAEs were reported. These data show the next-generation Eversense CGM system had sustained accuracy and safety up to 180 days, with an improved calibration scheme and survival, using the primary or SBA sensors.
